Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Focusing on patients with diabetes complicated with pulmonary infection, the purpose of this study is: 1) to identify the epidemiology, etiologic spectrum and status of diagnosis and treatment; 2) to explore the lower respiratory microenvironment and host immune response and then make an application in clinic.
Investigators perform a cross-sectional multicenter study on patients with pulmonary infection. All patients receive clinical questionnaires, laboratory examinations and treatment monitoring. Routine clinical pathogen culture and mNGS are both carried out on pathogen detection. Among participants in IDSeq UltraTM group, 1:2 nested case-control study is carried out involving 77 cases from pulmonary-infected group paired with 154 control cases and peripheral blood RNA-seq is carried out between pneumonia patients with diabetes and pneumonia patients without diabetes matched for gender, age and fasting blood-glucose.
The final purpose is to find out the difference in etiologic spectrum and host immune on lower respiratory infection between diabetes patients and controls. Now investigators wish to register this study to do a further research, in order to improve the diagnosis value of diabetes complicated with pulmonary infection and to reduce the mortality.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pulmonary Infection with DM group | Patients with diabetes and pulmonary infection |
| |
| Pulmonary Infection group | Patients with pulmonary infection while the fasting blood-glucose in the normal range. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| mNGS, IDSeq UltraTM | Diagnostic Test | pathogen detection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Survival at 28 Days | 28 days from date of diagnosis of pulmonary infection until the date of death from any cause | 28 days from date of diagnosis of pulmonary infection until the date of death from any cause, whichever came first |
| Survival at 14 Days | 14 days from date of diagnosis of pulmonary infection until the date of death from any cause | 14 days from date of diagnosis of pulmonary infection until the date of death from any cause, whichever came first |
| Survival at 7 Days | 7 days from date of diagnosis of pulmonary infection until the date of death from any cause | 7 days from date of diagnosis of pulmonary infection until the date of death from any cause, whichever came first |
| Measure | Description | Time Frame |
|---|---|---|
| 72h Treatment Response | response after infection treating 72 hours | disease treating 72 hours |
| Hospitalization Time | the time of hospital stay including ordinary sickroom and ICU of patients from different groups |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Min Zhou, Ph.D., M.D. | Contact | +8613681779642 | doctor_zhou_99@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Jieming Qu, Ph.D., M.D. | China, Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ruijin Hospital Shanghai Jiao Tong University School of Medicine | Recruiting | Shanghai | Shanghai Municipality | 200025 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Every 6 months from date of diagnosis of pulmonary infection until the date of death from any cause, assessed up to 3 years |
| CURB-65 Score | Differences in confusion, urea, respiratory rate and age 65 scoring system from different groups. | Every 6 months from date of diagnosis of pulmonary infection until the date of death from any cause, assessed up to 3 years |
| Inflammatory Parameters | Differences in CRP, PCT, IL-6, IL-8, TNF-α from different groups. | Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years |
| Cell-mediated Immunoserologic Indexs | Differences of CD3, CD4 and CD8 in different groups in order to research on cell-mediated immunity of patients with or without diabetes and pulmonary infection | Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years |
| PSI Indexs | Pneumonia severity index grade, including age, comorbidities, signs, blood gases | Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years |
| SOFA Indexs | Sequential Organ Failure Assessment | Day 0, day 3, day7-14 and final result from date of diagnosis of pulmonary infection until the date of death or cure from any cause, assessed up to 1 years |